A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma

被引：0
|
作者：
O'Day, Steven
Gonzalez, Rene
Kim, Kevin
Chmielowski, Bartosz
Kefford, Richard
Long, Georgina
Loquai, Carmen
Cowey, Charles Lance
Hauschild, Axel
Hainsworth, John D.
Hersey, Peter
Boyle, Frances
Evans, T. R. Jeffry
Hamid, Omid
Meneses, Nicole
Andresen, Corina
Ren, Min
O'Brien, James P.
Flaherty, Keith
机构：
[1] Beverly Hills Canc Ctr, Beverly Hills, CA USA
[2] UCHSC, Aurora, CO USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Univ Calif Los Angeles, Los Angeles, CA USA
[5] Westmead Hosp, Westmead, NSW 2145, Australia
[6] Univ Sydney, Sydney, NSW 2006, Australia
[7] Johannes Gutenberg Univ Mainz, Univ Med, D-55122 Mainz, Germany
[8] Texas Oncol, Dallas, TX USA
[9] Univ Klinikum Schleswig Holstein, Kiel, Germany
[10] Sarah Cannon Res Inst, Nashville, TN USA
[11] Tennessee Oncol, Nashville, TN USA
[12] Calvary Mater Newcastle, Waratah, Australia
[13] Melanoma Inst Australia, Sydney, NSW, Australia
[14] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[15] Angeles Clin & Res Inst, Los Angeles, CA USA
[16] Eisai Inc, Woodcliff Lake, NJ USA
[17] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9026
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma
    Sinik, Lenka
    Minson, Katherine A.
    Tentler, John J.
    Carrico, Jacqueline
    Bagby, Stacey M.
    Robinson, William A.
    Kami, Rotem
    Burstyn-Cohen, Tal
    Eckhardt, S. Gail
    Wang, Xiaodong
    Frye, Stephen, V
    Earp, H. Shelton
    DeRyckere, Deborah
    Graham, Douglas K.
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (02) : 278 - 288
  • [42] A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer
    Goodwin, Rachel
    Jonker, Derek
    Chen, Eric
    Kennecke, Hagen
    Cabanero, Michael
    Tsao, Ming-Sound
    Vickers, Michael
    Bohemier, Caryn
    Lim, Howard
    Ritter, Heather
    Tu, Dongsheng
    Seymour, Lesley
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (04) : 1077 - 1084
  • [43] Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal Cancer
    Sorah, Jonathan D.
    Moore, Dominic T.
    Reilley, Matthew J.
    Salem, Mohamed E.
    Triglianos, Tammy
    Sanoff, Hanna K.
    McRee, Autumn J.
    Lee, Michael S.
    ONCOLOGIST, 2022, 27 (12): : 1006 - E930
  • [44] A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer
    Rachel Goodwin
    Derek Jonker
    Eric Chen
    Hagen Kennecke
    Michael Cabanero
    Ming-Sound Tsao
    Michael Vickers
    Caryn Bohemier
    Howard Lim
    Heather Ritter
    Dongsheng Tu
    Lesley Seymour
    Investigational New Drugs, 2020, 38 : 1077 - 1084
  • [45] The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial
    Algazi, A. P.
    Cha, E.
    Ortiz-Urda, S. M.
    McCalmont, T.
    Bastian, B. C.
    Hwang, J.
    Pampaloni, M. H.
    Behr, S.
    Chong, K.
    Cortez, B.
    Quiroz, A.
    Coakley, F.
    Liu, S.
    Daud, A. I.
    BRITISH JOURNAL OF CANCER, 2015, 112 (08) : 1326 - 1331
  • [46] The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial
    A P Algazi
    E Cha
    S M Ortiz-Urda
    T McCalmont
    B C Bastian
    J Hwang
    M H Pampaloni
    S Behr
    K Chong
    B Cortez
    A Quiroz
    F Coakley
    S Liu
    A I Daud
    British Journal of Cancer, 2015, 112 : 1326 - 1331
  • [47] Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors
    Ming, Zizhen
    Lim, Su Yin
    Kefford, Richard F.
    Rizos, Helen
    PIGMENT CELL & MELANOMA RESEARCH, 2020, 33 (02) : 345 - 357
  • [48] A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia
    Bohensky, Megan A.
    Pasupathi, Kumar
    Gorelik, Alexandra
    Kim, Hansoo
    Harrison, James P.
    Liew, Danny
    VALUE IN HEALTH, 2016, 19 (08) : 1009 - 1015
  • [49] A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors
    Shinji Nakamichi
    Hiroshi Nokihara
    Noboru Yamamoto
    Yasuhide Yamada
    Kazunori Honda
    Yosuke Tamura
    Hiroshi Wakui
    Tatsuya Sasaki
    Wataru Yusa
    Katsuki Fujino
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 1153 - 1161
  • [50] A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors
    Nakamichi, Shinji
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Yamada, Yasuhide
    Honda, Kazunori
    Tamura, Yosuke
    Wakui, Hiroshi
    Sasaki, Tatsuya
    Yusa, Wataru
    Fujino, Katsuki
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (06) : 1153 - 1161
12345